Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4681950 | 0.80 | L3MBTL1 (0.42) | THRBTHRAMAPTHPGDLMNA | |
| SCHEMBL16599513 | 0.78 | HSD17B10 (0.36) | THRBTHRAMAPTHPGDLMNA | |
| SCHEMBL4685977 | 0.78 | THRA (0.46) | THRBTHRAHPGDLMNASMN1; SMN2 | |
| SCHEMBL30468864 | 0.78 | THRA (0.46) | THRBTHRAHPGDLMNASMN1; SMN2 | |
| SCHEMBL19463829 | 0.77 | THRA (0.43) | THRBTHRAMAPTHPGDLMNA | |
| SCHEMBL16615504 | 0.76 | THRA (0.38) | THRBTHRAHPGDLMNAALDH1A1 | |
| SCHEMBL4688019 | 0.75 | HTR1A (0.43) | MAPTLMNAALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL9237762 | 0.75 | BCHE (0.49) | LMNAL3MBTL1BCHEKDM4E | |
| SCHEMBL4684596 | 0.74 | ALDH1A1 (0.50) | THRBTHRAMAPTHPGDLMNA | |
| SCHEMBL14159705 | 0.74 | MEN1 (0.44) | THRBMAPTHPGDLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3389380-B1 | SPIROCYCLIC QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3389380-B1 | SPIROCYCLIC QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3303341-B1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING HIV INFECTION | MERCK SHARP & DOHME (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3285582-B1 | PHOSPHATE-SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3285582-B1 | PHOSPHATE-SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10544155-B2 | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10233193-B2 | Fused tricyclic heterocyclic compounds useful for treating HIV infection | MERCK SHARP & DOHME CORP. (US) | 2019-03-19 | — | — | US | disclosed |
| US-10201533-B2 | Substituted quinolizine derivatives useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10201533-B2 | Substituted quinolizine derivatives useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20190040076-A1 | Spirocyclic Quinolizine Derivatives Useful as HIV Integrase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-07 | — | — | US | disclosed |
| US-20180028509-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9861620-B2 | Substituted quinolizine derivatives useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-01-09 | — | — | US | disclosed |
| WO-2017106071-A1 | SPIROCYCLIC QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017106071-A1 | SPIROCYCLIC QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2016154527-A1 | PHOSPHATE-SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
| US-20160228419-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-11 | — | — | US | disclosed |
| EP-3049081-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015048363-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-02 | — | — | WO | disclosed |
| EP-1973906-A1 | HYDROXYDIHYDROPYRIDOPY RAZINE-1,8-DIONES AND METHODS FOR INHIBITING HIV INTEGRASE | Virochem Pharma Inc. (CA) | 2008-10-01 | — | — | EP | disclosed |
| WO-2006066414-A1 | HYDROXYDIHYDROPYRIDOPY RAZINE-1,8-DIONES AND METHODS FOR INHIBITING HIV INTEGRASE | VIROCHEM PHARMA INC. (CA) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233193-B2 | Fused tricyclic heterocyclic compounds useful for treating HIV infection | CXCR4, CCR5, CXCR1 | THRB 2879/4885THRA 3073/4885MAPT 3027/4885 |
| US-10544155-B2 | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors | NQO2, SIRT5, CCR5 | THRB 2596/4885THRA 2307/4885MAPT 3508/4885 |
| US-20190040076-A1 | Spirocyclic Quinolizine Derivatives Useful as HIV Integrase Inhibitors | NQO2, SIRT5, CCR5 | THRB 2596/4885THRA 2307/4885MAPT 3508/4885 |
| US-20160228419-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | NQO2, CYP3A5, QTRT1 | THRB 3636/4885THRA 3454/4885MAPT 3742/4885 |
| US-20180028509-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | NQO2, CYP3A5, QTRT1 | THRB 3636/4885THRA 3454/4885MAPT 3742/4885 |
| US-10201533-B2 | Substituted quinolizine derivatives useful as HIV integrase inhibitors | NQO2, CYP3A5, QTRT1 | THRB 3636/4885THRA 3454/4885MAPT 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.